You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227
|
|---|---|
| Published in |
Frontiers in Medicine, November 2022
|
| DOI | 10.3389/fmed.2022.1030094 |
| Pubmed ID | |
| Authors |
Peter M. Anderson, Vivek Subbiah, Matteo M. Trucco |
| Abstract |
Osteosarcoma is a high-grade sarcoma characterized by osteoid formation, nearly universal expression of IGF1R and with a subset expressing HER-2. These qualities provide opportunities for the use of the alpha particle-emitting isotopes to provide targeted radiation therapy via alpha particles precisely to bone-forming tumors in addition to IFG1R or Her-2 expressing metastases. This review will detail experience using the alpha emitter radium-223 (223Ra, tradename Xofigo), that targets bone formation, in osteosarcoma, specifically related to patient selection, use of gemcitabine for radio-sensitization, and using denosumab to increasing the osteoblastic phenotype of these cancers. A case of an inoperable left upper lobe vertebral-paraspinal-mediastinal osteoblastic lesion treated successfully with 223Ra combined with gemcitabine is described. Because not all areas of osteosarcoma lesions are osteoblastic, but nearly all osteosarcoma cells overexpress IGF1R, and some subsets expressing Her-2, the anti-IGF1R antibody FPI-1434 linked to actinium-225 (225Ac) or the Her-2 antibody linked to thorium-227 (227Th) may become other means to provide targeted alpha particle therapy against osteosarcoma (NCT03746431 and NCT04147819). |
X Demographics
The data shown below were collected from the profiles of 24 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 11 | 46% |
| France | 3 | 13% |
| Germany | 1 | 4% |
| India | 1 | 4% |
| Greece | 1 | 4% |
| Spain | 1 | 4% |
| Unknown | 6 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 15 | 63% |
| Scientists | 4 | 17% |
| Practitioners (doctors, other healthcare professionals) | 4 | 17% |
| Science communicators (journalists, bloggers, editors) | 1 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 6 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 6 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Unspecified | 1 | 17% |
| Student > Ph. D. Student | 1 | 17% |
| Student > Bachelor | 1 | 17% |
| Other | 1 | 17% |
| Unknown | 2 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Unspecified | 1 | 17% |
| Biochemistry, Genetics and Molecular Biology | 1 | 17% |
| Medicine and Dentistry | 1 | 17% |
| Unknown | 3 | 50% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 March 2023.
All research outputs
#2,679,414
of 25,545,162 outputs
Outputs from Frontiers in Medicine
#784
of 7,241 outputs
Outputs of similar age
#52,821
of 430,212 outputs
Outputs of similar age from Frontiers in Medicine
#36
of 465 outputs
Altmetric has tracked 25,545,162 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,241 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.6. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 430,212 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 465 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.